Zanubrutinib-induced liver injury: a case report and literature review

BACKGROUND: Zanubrutinib is a Bruton’s tyrosine kinase inhibitor that has been recently licensed in refractory mantle cell lymphoma and under assessment in phase 3 clinical trials for other B cell malignancies. To date, there are no reported cases of hepatotoxicity secondary to zanubrutinib. We repo...

Descripción completa

Detalles Bibliográficos
Autores principales: Atallah, Edmond, Wijayasiri, Pramudi, Cianci, Nicole, Abdullah, Khorrum, Mukherjee, Abhik, Aithal, Guruprasad P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164809/
https://www.ncbi.nlm.nih.gov/pubmed/34051727
http://dx.doi.org/10.1186/s12876-021-01825-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164809/
https://www.ncbi.nlm.nih.gov/pubmed/34051727
http://dx.doi.org/10.1186/s12876-021-01825-2

Ejemplares similares